Guardant Health (NASDAQ:GH) Issues Earnings Results, Misses Expectations By $0.15 EPS

Guardant Health (NASDAQ:GH) released its quarterly earnings results on Thursday. The company reported ($0.90) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.75) by ($0.15), Zacks reports. Guardant Health had a negative net margin of 74.02% and a negative return on equity of 1,200.44%. Guardant Health updated its FY 2025 guidance to EPS.

Guardant Health Stock Performance

Shares of NASDAQ GH traded down $1.60 during trading on Thursday, hitting $47.40. 3,021,452 shares of the company were exchanged, compared to its average volume of 2,468,429. The firm has a market capitalization of $5.86 billion, a PE ratio of -11.18 and a beta of 1.32. The company has a fifty day moving average price of $39.78 and a 200-day moving average price of $31.39. Guardant Health has a 12-month low of $15.81 and a 12-month high of $50.89.

Wall Street Analysts Forecast Growth

GH has been the topic of a number of research analyst reports. JPMorgan Chase & Co. lifted their price target on shares of Guardant Health from $48.00 to $50.00 and gave the company an “overweight” rating in a research note on Thursday, November 7th. Guggenheim reissued a “buy” rating on shares of Guardant Health in a research note on Wednesday, January 22nd. Sanford C. Bernstein decreased their price objective on Guardant Health from $40.00 to $35.00 and set an “outperform” rating on the stock in a report on Wednesday, October 30th. The Goldman Sachs Group raised their price objective on Guardant Health from $36.00 to $49.00 and gave the company a “buy” rating in a report on Tuesday, January 28th. Finally, Barclays assumed coverage on Guardant Health in a report on Thursday, January 23rd. They issued an “overweight” rating and a $60.00 price objective on the stock. Sixteen analysts have rated the stock with a buy rating, According to MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus price target of $42.63.

Insider Buying and Selling at Guardant Health

In other Guardant Health news, Director Musa Tariq sold 2,320 shares of Guardant Health stock in a transaction dated Friday, December 13th. The stock was sold at an average price of $35.00, for a total value of $81,200.00. Following the completion of the transaction, the director now directly owns 2,676 shares of the company’s stock, valued at $93,660. The trade was a 46.44 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Insiders sold a total of 2,652 shares of company stock valued at $93,192 in the last three months. 5.50% of the stock is owned by corporate insiders.

Guardant Health Company Profile

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.